Cargando…

Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study

BACKGROUND: Biologic therapy resulted in a significant positive impact on the management of inflammatory bowel disease (IBD) however data on the efficacy and side effects of these therapies in the elderly is scant. AIM: To evaluate retrospectively the drug sustainability, effectiveness, and safety o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hahn, Gustavo Drügg, LeBlanc, Jean-Frédéric, Golovics, Petra Anna, Wetwittayakhlang, Panu, Qatomah, Abdulrahman, Wang, Anna, Boodaghians, Levon, Liu Chen Kiow, Jeremy, Al Ali, Maryam, Wild, Gary, Afif, Waqqas, Bitton, Alain, Lakatos, Peter Laszlo, Bessissow, Talat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Retrospective Cohort Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476849/ https://www.ncbi.nlm.nih.gov/pubmed/36156919 http://dx.doi.org/10.3748/wjg.v28.i33.4823

Ejemplares similares

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015
por: Golovics, Petra Anna, et al.
Publicado: (2022)

Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn’s Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Hereditary Nonpolyposis Colorectal Cancer in Association with Crohn's Disease and Lynch Syndrome: The Importance of a Strict Endoscopic Surveillance
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Wetwittayakhlang, P, et al.
Publicado: (2022)

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

A143 SAFETY OF BIOLOGICAL THERAPIES IN ELDERLY IBD: A SYSTEMATIC REVIEW
por: Golovics, P, et al.
Publicado: (2022)

Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
por: Albader, Farah, et al.
Publicado: (2021)

Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease
por: Chao, Che-Yung, et al.
Publicado: (2019)

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases
por: Kablawi, Dana, et al.
Publicado: (2023)

The Optimal Management of Fistulizing Crohn’s Disease: Evidence beyond Randomized Clinical Trials
por: Wetwittayakhlang, Panu, et al.
Publicado: (2022)

Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians
por: Hart, Lara, et al.
Publicado: (2020)

A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
por: Yanofsky, R, et al.
Publicado: (2022)

Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes
por: Nene, Sofia, et al.
Publicado: (2020)

Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review
por: Al Khoury, Alex, et al.
Publicado: (2021)

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease
por: Alrajhi, Saad, et al.
Publicado: (2020)

Time Trends of Environmental and Socioeconomic Risk Factors in Patients with Inflammatory Bowel Disease over 40 Years: A Population-Based Inception Cohort 1977–2020
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape
por: LeBlanc, Jean-Frédéric, et al.
Publicado: (2019)

Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity—A Retrospective Study
por: Benmassaoud, Amine, et al.
Publicado: (2016)

Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?
por: Gonczi, Lorant, et al.
Publicado: (2019)

Regional variation of pediatric inflammatory bowel disease in Saudi Arabia: Results from a multicenter study
por: El Mouzan, Mohammad I, et al.
Publicado: (2020)

A191 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kablawi, D, et al.
Publicado: (2023)

Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease
por: Kostas, Athanasios, et al.
Publicado: (2017)

Preoperative bowel preparation does not favor the management of colorectal anastomotic leak
por: Zorbas, Konstantinos A, et al.
Publicado: (2019)

Fecal lactoferrin accurately reflects mucosal inflammation in inflammatory bowel disease
por: Rubio, Marrieth G, et al.
Publicado: (2019)

Predicting the outcome of closed-loop small bowel obstruction by preoperative characteristics
por: Toneman, Masja K, et al.
Publicado: (2022)

Benefits of laparoscopy-assisted ileostomy in colorectal cancer patients with bowel obstruction
por: Wang, Yi-Jie, et al.
Publicado: (2023)

Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017)

Trends in medication use and treatment patterns in Chinese patients with inflammatory bowel disease
por: Yao, Ling-Ya, et al.
Publicado: (2022)

High prevalence of cholestasis, with increased conjugated bile acids in inflammatory bowel diseases patients
por: Girardin, Marc, et al.
Publicado: (2018)

Nomogram for predicting transmural bowel infarction in patients with acute superior mesenteric venous thrombosis
por: Jiang, Meng, et al.
Publicado: (2020)

Evaluation of bacterial biomarkers to aid in challenging inflammatory bowel diseases diagnostics and subtype classification
por: Lopez-Siles, Mireia, et al.
Publicado: (2020)

Hospital costs, length of stay and prevalence of hip and knee arthroplasty in patients with inflammatory bowel disease
por: Ehrenpreis, Eli D, et al.
Publicado: (2017)

Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy
por: Rubin, Samuel J S, et al.
Publicado: (2022)

Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America
por: Fortes, Flora Maria Lorenzo, et al.
Publicado: (2020)

Comprehensively evaluate the short outcome of small bowel obstruction: A novel medical-economic score system
por: Xu, Wei-Xuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1ce0qqnn1tn13nnkk86ktveka7